Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis
Tuberculosis (TB) claims nearly 1.5 million lives annually. Current TB treatment requires a combination of several drugs administered for at least 6 months. Mycobacterium tuberculosis (Mtb), the causative agent of TB, can persist in infected humans and animals for decades. Moreover, during infection...
Main Authors: | Sarah M. Glenn, Obolbek Turapov, Vadim Makarov, Douglas B. Kell, Galina V. Mukamolova |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2022.957287/full |
Similar Items
-
<i>Mycobacterium tuberculosis</i> Dormancy: How to Fight a Hidden Danger
by: Elena G. Salina, et al.
Published: (2022-11-01) -
An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis
by: Styliani Karanika, et al.
Published: (2022-09-01) -
Tuberculosis: The success tale of less explored dormant Mycobacterium tuberculosis
by: Akanksha Verma, et al.
Published: (2022-12-01) -
A Mycobacterium tuberculosis Effector Targets Mitochondrion, Controls Energy Metabolism, and Limits Cytochrome c Exit
by: Marianne Martin, et al.
Published: (2023-06-01) -
Insights into the molecular determinants involved in Mycobacterium tuberculosis persistence and their therapeutic implications
by: Hemant Joshi, et al.
Published: (2021-12-01)